Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Viventia Bio Inc (OQ:VITA)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for VITA*US within the last 6 months
Loading...
See all filings within the past 6 months

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
5.94
3.14
Price to Book - most recent quarter
--
2.19
2.08
Price to Cash Flow per share - TTM
--
17.66
13.73
Price to Free Cash Flow per share - TTM
--
16.96
23.65
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Viventia Bio Inc is a Canada-based biological company. The Company is a biologics oncology company focused on designing, engineering and developing targeted protein therapeutics. The Company's advanced product candidates, Vicinium and Proxinium, are locally administered TPTs. The Company is engaged in developing next generation oncology therapeutics utilizing the Targeted Protein Therapeutic technology (TPT). The TPTs has been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates. The Company is engaged in designing, engineering, developing and commercializing TPTs to identify and address patients with cancers that has a high unmet medical needs.

See business summary

 

Twitter

Search (past week) for $VITA

  • No tweets found